High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy

Muscle and Nerve

Volumn 34, Issue 2, 2006, Pages 246-250

  Brannagan III, Thomas H ^a   Alaedini, Armin ^a   Gladstone, Douglas E ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Autoimmune disease; Conduction block; Cyclophosphamide; GM1 antibodies; Multifocal motor neuropathy

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; ETANERCEPT; FLUCONAZOLE; FLUDARABINE; GANGLIOSIDE GM1; GANGLIOSIDE GM1 ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN M ANTIBODY; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AMPLITUDE MODULATION; ANTIBODY TITER; ARTICLE; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELECTROMYOGRAPHY; FEMALE; HUMAN; MOTOR NEUROPATHY; MULTIFOCAL MOTOR NEUROPATHY; MUSCLE STRENGTH; NERVE CONDUCTION; NERVE POTENTIAL; NEUTROPHIL COUNT; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; PROPHYLAXIS; RANKIN SCALE; REMISSION; STEM CELL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CYCLOPHOSPHAMIDE; DRUG RESISTANCE; EVOKED POTENTIALS, MOTOR; FEMALE; HUMANS; LEUKOCYTE COUNT; MIDDLE AGED; MOTOR NEURON DISEASE; NEURAL CONDUCTION; NEUROLOGIC EXAMINATION; NEUTROPHILS; PERIPHERAL NERVES;

EID: 33746748791     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.20524     Document Type: Article

References (42)

1. Alaedini A, Wirguin I, Latov N. Ganglioside agglutination immunoassay for rapid detection of autoantibodies in immune-mediated neuropathy. J Clin Lab Anal 2001;15:96-99.
2. Benedetti L, Grandis M, Nobbio L, Beronio A, Ghiglione E, Manzino M, et al. Mycophenolate mofetil in dysimmune neuropathies: a preliminary study. Muscle Nerve 2004;29:748-749.
3. Brannagan TH, Pradhan A, Heiman-Patterson T, Winkelman AC, Styler MJ, Topolsky DL, et al. High-dose cyclophosphamide without stem-cell rescue for refractory CIDP. Neurology 2002;58:1856-1858.
4. Brannagan TH, Pradhan A, Heiman-Patterson T, Winkleman AC, Styler MJ, Topolsky DL, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory chronic inflammatory demyelinating polyneuropathy (CIDP) and other immune-mediated neuropathies. Neurology 2001;56:A204.
5. Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, et al. Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998;129:1031-1035.
6. Brodsky RA, Sensenbrenner LL, Smith BD, Dorr D, Seaman PJ, Lee SM, et al. Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med 2001;135:477-483.
7. Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998;50:1480-1482.
8. Chaudhry V, Corse AM, Cornblath DR, Kund RW, Drachman DB, Freimer ML, et al. Multilocal motor neuropathy-response to human immune globulin. Ann Neurol 1993;33:237-242.
9. de Carvalho M, Luis ML. Relapsing chronic low-dose corticosteroid- responsive multilocal motor neuropathy with conduction block. Electromyogr Clin Neurophysiol 1997;37:95-97.
10. Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, et al. Pure motor demyelinating neuropathy-deterioration alter steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1994;57:778-783.
11. Drachman DB, Jones RJ, Brodsky RA. Treatment of refractory myasthenia: "Rebooting" with high-dose cyclophosphamide. Ann Neurol 2003;53:29-34.
12. Elliott JL, Pestronk A. Progression of multifocal motor neuropathy during apparently successful treatment with human-immunoglobulin. Neurology 1994;44:967-968.
13. Federico P, Zochoduc DW, Hahn AF, Brown WF, Feasby TE. Multifocal motor neuropathy improved by IVIg - randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-1262.
14. Feldman KL, Bromberg MB, Albers JW, Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 1991;30:397-401.
15. Gladstone DE, Brannagan TH III, Schwartzman RJ, Prestrud AA, Brodsky I. High-dose cyclophosphamide for severe refractory myasthenia gravis. J Neurol Neurosurg Psychiatry 2004;75:789-791.
16. Gladstone DE, Prestrud AA, Brannagan TH III. High-dose cyclophosphamide results in long-term disease remission with restoration of a normal quality ol life in patients with severe refractory chronic inflammatory demyelinating polyneuropathy. J Peripher Nerv Syst 2005;10:11-16.
17. Gladstone DE, Prestrud AA, Pradhan A, Styler MJ, Topolsky DL, Crilley PA, et al. High-dose cyclophosphamide for severe systemic lupus erythematosus. Lupus 2002;11:405-410.
18. Hughes PR. 79th ENMC International Workshop: multifocal motor neuropailiy. 14-15 April 2000, Hilversum. The Netherlands. Neuromuscul Disord 2001;11:309-314.
19. Jones RJ, Barber JP, Vala MS, Collector MI, Kaufmann SH, Ludeman SM, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995;85:2742-2746.
20. Kaji R, Shibasaki H, Kimura J. Multifocal demyelinatiug motor neuropathy-cranial nerve involvement and immunoglobulin therapy. Neurology 1992;42:506-509.
21. Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 2004;30:131-156.
22. Komiyama A, Toda H, Hasegawa O, Kuroiwa Y. Multifocal motor neuropathy. Neurology 1998;50:314.
23. Krarup C, Stewart JD, Sumner AJ, Pestronk A, Lipton SA. A syndrome of asymmetric limb weakness with motor conduction block. Neurology 1990;40:118-127.
24. Lee G, Jeong Y, Wirguin I, Hays AP, Willison HJ, Latov N. Induction of human IgM and IgG anti-GMI antibodies in transgenic mice in response to lipopolysaccharidcs from Campylobacter jejuni. J Neuroimmnnol 2004;146:63-75.
25. Martina IS, van Doorn PA, Schmitz PI, Meulstee J, van der Meche FG. Chronic motor neuropathies: response to inter-feron-beta1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 1999;66:197-201.
26. Meucci N, Nobilcorazio K, Barbieri S, Cappellari A, Scarlato G. Long-term follow up ol multifocal motor neuropathy patients treated with intravenous immunoglobulins and oral cyclophosphamide. Neurology 1990;46:3027.
27. Nagamatsu M, Terao S, Misu K, Li M, Hattori N, Ichimura M, et al. Axonal and perikaryal involvement in chronic inflammatory demyelinatiug polyneuropathy. J Neurol Neurosurg Psychiatry 1999;66:727-733.
28. Nemni R, Santuccio G, Calabrese E, Galardi G, Canal N. Efficacy of cyclosporine treatment in multilocal motor neuropathy. J Neurol 2003;250:1118-1120.
29. Parry GJ, Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 1988;11:103-107.
30. Pestronk A, Cornblath DR, Ilyas AA, Baba M, Quarles RH, Griffin JW, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-78.
31. Pestronk A, Florence J, Miller T, Choksi R, Al Lozi MT, Levine TD. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003;74:485-489.
32. Petri M, Jones RJ, Brodsky RA. High-close cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003;48:166-173.
33. Popat U, Krance R. Haematopoietic stem cell transplantation for autoimmune disorders: the American perspective. Br J Haematol 2004;126:637-649.
34. Radis CD, Kahl LL, Baker GL, Wasko MCM, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid-arthritis - a 20-year follow-up-study. Arthritis Rheum 1995;38:1120-1127.
35. Rojas-Garcia R, Gallardo L, de Andres I, de Luna N, Juarez C, Sanchez P et al. Chronic neuropathy with IgM antiganglioside antibodies: Lack of long-term response to rituximab. Neurology 2003;01:1814-1816.
36. Ruegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004;63:2178-2179.
37. Sheikh KA, Zhang G, Gong Y, Schnaar RL, Griffin JW. An anti-ganglioside antibody-secreting hybridoma induces neuropathy in mice. Ann Neurol 2004;56:228-239.
38. Sherman WH, Latov N, Lange D, Havs R, Younger D. Fludarabine for IgM antibody-mediated neuropathies. Ann Neurol 1994;36:326-327.
39. Susuki K, Nishimoto Y, Yamada M, Baba M, Ueda S, Hirata K et al. Acute motor axoual neuropathy rabbit model: immune attack on nerve root axons. Ann Neurol 2003;54:383-388.
40. Terenghi F, Cappellari A, Bersano A, Carpo M, Barbieri S, Nobile-Orazio L. How long is IVIg effective in multifocal motor neuropathy? Neurology 2004;62:666-668.
41. van Asseldonk JTH, van den Berg LH, Berg-Vos RM, Wieneke GH, Wokke JHJ, Franssen H. Demyelination and axonal loss in multifocal motor neuropathy: distribution and relation to weakness. Brain 2003;126:186-198.
42. vandenBerg LH, Lokhorst H, Wokke JHJ. Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy. Neurology 1997;48:1135.